Genmab A/S (OTCMKTS:GNMSF) Stock Price Crosses Above Fifty Day Moving Average - Here's What Happened

Key Points

• Genmab A/S shares surpassed their fifty-day moving average of $229.39, trading as high as $277.60 during the session.
• The company reported earnings of $5.42 per share for the last quarter, exceeding estimates by $1.43, with a net margin of 37.53%.
• Genmab A/S has a market capitalization of $18.34 billion and continues to develop innovative antibody therapeutics for cancer treatment.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) shares crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $229.39 and traded as high as $277.60. Genmab A/S shares last traded at $277.60, with a volume of 10 shares.

Genmab A/S Price Performance

The firm has a market cap of $18.34 billion, a price-to-earnings ratio of 13.94 and a beta of 0.90. The firm's 50 day moving average price is $229.39 and its two-hundred day moving average price is $213.59.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $5.42 earnings per share for the quarter, topping the consensus estimate of $3.99 by $1.43. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The business had revenue of $925.00 million during the quarter, compared to the consensus estimate of $949.06 million.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.